243 related articles for article (PubMed ID: 20125159)
21. Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX-based regimens in clinical routine.
Sieg N; Naendrup JH; Gödel P; Balke-Want H; Simon F; Deckert M; Gillessen S; Kreissl S; Bröckelmann PJ; Borchmann P; von Tresckow B; Heger JM
Eur J Haematol; 2021 Aug; 107(2):202-210. PubMed ID: 33960535
[TBL] [Abstract][Full Text] [Related]
22. High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma.
Chamberlain MC
J Neurooncol; 2016 Feb; 126(3):545-50. PubMed ID: 26563190
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Primary Central Nervous System Lymphoma with High-dose Methotrexate and Radiotherapy in HIV-negative Patients.
Jalaeikhoo H; Yekaninejad MS; Hajizamani S; Rahim F; Ahmadzadeh A; Keyhani M; Sadeghi Hariri B; Saki N
Arch Iran Med; 2015 Sep; 18(9):577-81. PubMed ID: 26317598
[TBL] [Abstract][Full Text] [Related]
24. High-dose methotrexate for elderly patients with primary CNS lymphoma.
Zhu JJ; Gerstner ER; Engler DA; Mrugala MM; Nugent W; Nierenberg K; Hochberg FH; Betensky RA; Batchelor TT
Neuro Oncol; 2009 Apr; 11(2):211-5. PubMed ID: 18757775
[TBL] [Abstract][Full Text] [Related]
25. Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients.
Sarid N; Bokstein F; Blumenthal DT; Weiss-Meilik A; Gibstein L; Avivi I; Perry C; Ram R
J Neurooncol; 2021 Jan; 151(2):211-220. PubMed ID: 33099747
[TBL] [Abstract][Full Text] [Related]
26. Carboxypeptidase G2 rescue after high-dose methotrexate.
DeAngelis LM; Tong WP; Lin S; Fleisher M; Bertino JR
J Clin Oncol; 1996 Jul; 14(7):2145-9. PubMed ID: 8683248
[TBL] [Abstract][Full Text] [Related]
27. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
[TBL] [Abstract][Full Text] [Related]
28. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.
Puckrin R; El Darsa H; Ghosh S; Peters A; Owen C; Stewart D
Am J Hematol; 2021 Jul; 96(7):764-771. PubMed ID: 33811794
[TBL] [Abstract][Full Text] [Related]
29. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
Yu J; Du H; Ye X; Zhang L; Xiao H
Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
[TBL] [Abstract][Full Text] [Related]
30. A multicenter study of treatment of primary CNS lymphoma.
Ferreri AJ; Reni M; Pasini F; Calderoni A; Tirelli U; Pivnik A; Aondio GM; Ferrarese F; Gomez H; Ponzoni M; Borisch B; Berger F; Chassagne C; Iuzzolino P; Carbone A; Weis J; Pedrinis E; Motta T; Jouvet A; Barbui T; Cavalli F; Blay JY
Neurology; 2002 May; 58(10):1513-20. PubMed ID: 12034789
[TBL] [Abstract][Full Text] [Related]
31. Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma.
Mei S; Li X; Jiang X; Yu K; Lin S; Zhao Z
J Pharm Sci; 2018 May; 107(5):1454-1460. PubMed ID: 29331383
[TBL] [Abstract][Full Text] [Related]
32. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
[TBL] [Abstract][Full Text] [Related]
33. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.
Holdhoff M; Ambady P; Abdelaziz A; Sarai G; Bonekamp D; Blakeley J; Grossman SA; Ye X
Neurology; 2014 Jul; 83(3):235-9. PubMed ID: 24928128
[TBL] [Abstract][Full Text] [Related]
34. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
[TBL] [Abstract][Full Text] [Related]
35. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients.
Kawakatsu S; Nikanjam M; Lin M; Le S; Saunders I; Kuo DJ; Capparelli EV
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1339-1348. PubMed ID: 31586225
[TBL] [Abstract][Full Text] [Related]
37. Outcome of patients with newly diagnosed primary CNS lymphoma after high-dose methotrexate followed by consolidation whole-brain radiotherapy and cytarabine: an 8-year cohort study.
Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Tantiworawit A; Norasetthada L
Int J Clin Oncol; 2021 Oct; 26(10):1805-1811. PubMed ID: 34236556
[TBL] [Abstract][Full Text] [Related]
38. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
39. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma.
Joerger M; Huitema AD; Illerhaus G; Ferreri AJ
Leuk Lymphoma; 2012 Oct; 53(10):1867-75. PubMed ID: 22530664
[TBL] [Abstract][Full Text] [Related]
40. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
